Table F-7. Key Question 2 studies with a third outcome

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Author, Year** | **Groups** | **Outcome #3, Exact Measure Used** | **Timing of Measurement,**  **Data Source** | **N analyzed for This Outcome** | **Results by Group** | **Differences in Groups** | **Covariates Controlled for in Analysis, Statistical Methods Used** |
| Becker et al., 20084 | G1: Mailed guideline (Increase clinician reach)  G2: Guideline implementation (multicomponent, clinicians only)  G3: Guideline implementation and motivational counseling directed at patient (multicomponent, clinicians and patients) | Clinical outcomes (applicable for general public/patients)  Quality of life. Measured with the Euro-Qol and Fear Avoidance Beliefs Questionnaire. | Baseline, 6 month, 12 month  Self-report | Patient N baseline = 1378 G1: 479 G2: 489 G3: 410  N at 6 months=1261 G1: 450 G2: 435 G3: 376  N at 12 months=1211 G1: 425 G2: 421 G3: 365 | 6 months G1: M=66.85 G2: M=66.59 G3: M=67.54  12 months G1: M=67.65 G2: M=68.46 G3: M=70.38 | 6 months (author provided odds ratios for groups compared with control only) Mean diff (95% CI) G1 vs. G2: -0.25  (-2.86/2.36) G1 vs. G3: 0.69  (-1.92/3.30) G2 vs. G3: 0.943\* p=NR  12 months Mean diff (95% CI) G1 vs. G2: 0.80 (-1.74/3.34) G1 vs. G3: 2.72(0.19/5.26) G2 vs. G3: 1.919\* p=NR | Sex, age, fear avoidance, physical activity, and number of days in pain during previous 6 months |

Table F-7. Key question 2 studies with a third outcome (continued)

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author, Year** | | **Groups** | | **Outcome #3, Exact Measure Used** | | **Timing of Measurement,**  **Data Source** | | **N analyzed for This Outcome** | | **Results by Group** | | **Differences in Groups** | | **Covariates Controlled for in Analysis, Statistical Methods Used** | |
| Bekkering et al., 20055,6 | G1: Received guidelines by mail (increase reach)  G2: Received guidelines + active training strategy (multicomponent) | | Clinical outcomes (applicable for general public/patients)  Pain; measured using an 11-point NRS scale ranging from 0 (“no pain”) to 10 (“very severe pain”). | | Baseline, 6, 12, 26, and 52 weeks after baseline  Self-report | | Baseline Overall=511 patients G1: 259 patients G2: 256 patients 6 weeks Overall=511 patients G1: 259 patients G2: 256 patients 12 weeks Overall=511 patients G1: 259 patients G2: 256 patients 26 weeks Overall=511 patients G1: 259 patients G2: 256 patients 52 weeks Overall=511 patients G1: 259 patients G2: 256 patients | | Mean scores and interquartile ranges Baseline G1: 7.0 (5.0-8.0) G2: 7.0 (5.0-8.0) 6 weeks G1: 3.0 (2.0-5.0) G2: 3.0 (2.0-5.0) 12 weeks G1: 2.0 (1.0-4.0) G2: 2.0 (1.0-4.0) 26 weeks G1: 1.0 (0.0-4.0) G2: 2.0 (1.0-4.0) 52 weeks G1: 1.0 (0.3-3.0) G2: 2.0 (0.0-4.0) | | Adjusted absolute differences (G2-G1):  6 weeks:  0.16 (-0.35 to 0.69)  12 weeks:  0.34 (-0.19 to 0.88)  26 weeks:  0.62 (0.06 to 1.18)  52 weeks:  0.55 (-0.02 to 1.11) | | Sex, previous episode of back pain, duration of current episode of back pain, pain and coping inventory relaxation subscale. Clustering of practices, physical therapists, patients, time points.  Multilevel modeling; Wald chi-square tests | |

Table F-7. Key question 2 studies with a third outcome (continued)

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author, Year** | | **Groups** | | **Outcome #3, Exact Measure Used** | | **Timing of Measurement,**  **Data Source** | | **N analyzed for This Outcome** | | **Results by Group** | | **Differences in Groups** | | **Covariates Controlled for in Analysis, Statistical Methods Used** | |
| Bishop and Wing, 200641 | G1: Control (not abstracted)  G2: Physician only (increase reach)  G3: Physician and patient (multicomponent) | | Behavior (applicable for clinicians)  Guideline-concordant treatment advice for >12-week post injury treatment period. The compulsory WCB physician report forms were collected and scored. Dichotomous measure of 1 = presence of concordant/ discordant behavior. | | Once during 12-16 weeks  Workers’ Compensation Board reports | | >12 weeks Overall N=428 G2: 149 G3: 139 | | NR | | NR  NOTE: Authors did not analyze between groups difference from each other, nor provide any figures, tables, or data for the >12 week measures. | | NR | |

Table F-7. Key question 2 studies with a third outcome (continued)

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author, Year** | | **Groups** | | **Outcome #3, Exact Measure Used** | | **Timing of Measurement,**  **Data Source** | | **N analyzed for This Outcome** | | **Results by Group** | | **Differences in Groups** | | **Covariates Controlled for in Analysis, Statistical Methods Used** | |
| Campbell et al., 20047 | G1: Control (not abstracted)  G2: LHA (increase motivation)  G3: TPV (multicomponent)  G4: TPV and LHA (multicomponent) | | Health-related decisions or behavior (applicable for general public/patients)  CRC screening. Participants were asked whether they had ever had any CRC screening tests and, if so, how long ago (< 1 yr, 1-2 yrs, 2-5 yrs, or > 5 yrs). | | Baseline and 1 yr followup  Self-report | | N=587  G2: 123 G3: 159 G4: 176 | | FOBT test in the past year (%) Baseline G2: 23.5 G3: 19.7 G4: 19.5  Followup G2: 33.4 G3: 36.8 G4: 31.0  Other CRC test in the past year (%) Baseline G2: 19.6 G3: 23.7 G4: 26.4  Followup G2: 25.5 G3: 21.1 G4: 14.9 | | FOBT test  Baseline G2 vs. G3: 3.8 G2 vs. G4: 4.0 G3 vs. G4: 0.2 ns, p=0.36 Followup G2vs.G3: 3.4 G2vs.G4: 2.4 G3 vs.G4: 5.8 ns, p=0.08 Other CRC Baseline G2 vs. G3: 4.1 G2 vs. G4: 6.8 G3 vs. G4: 2.7 ns, p=0.75 Followup G2 vs. G3: 4.4 G2 vs. G4: 10.6 G3 vs. G4: 6.2 p=0.04 but looks like this is in comparison to controls | | Demographics  regression models | |

Table F-7. Key question 2 studies with a third outcome (continued)

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author, Year** | | **Groups** | | **Outcome #3, Exact Measure Used** | | **Timing of Measurement,**  **Data Source** | | **N analyzed for This Outcome** | | **Results by Group** | | **Differences in Groups** | | **Covariates Controlled for in Analysis, Statistical Methods Used** | |
| Feldstein et al., 200613 | G1: Usual care (not abstracted)  G2: EMR reminder (increase reach for clinicians)  G3: EMR reminder and patient reminder (via letter with educational materials (multicomponent) | | Behavioral intentions to use or apply the evidence  Total caloric expenditure from all activity from the Community Health Activities Model Program for Seniors questionnaire (a self-report physical activity questionnaire for older men and women) | | Baseline and 6 months post intervention  Patient self-report | | G1: 32; G2: 38;  G3: 38 | | G1: Pre: 2,325.7; Post: 1980.9  G2: Pre: 3,082.9; Post: 2312.7;  G3: Pre: 2,614.4; Post: 2525.9 | | Difference:  G1 vs. G2: -331.8  G1 vs. G3: -545  G2 vs. G3: -213.2 95% CI: NR p=0.32 treatment and UC | | Presurvey response  See Outcome #1 | |

Table F-7. Key question 2 studies with a third outcome (continued)

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author, Year** | **Groups** | | **Outcome #3, Exact Measure Used** | | **Timing of Measurement,**  **Data Source** | | **N analyzed for This Outcome** | | **Results by Group** | | **Differences in Groups** | | **Covariates Controlled for in Analysis, Statistical Methods Used** | |
| Hagmolen et al., 200815 | G1: Guideline dissemination (increase reach)  G2: Guideline dissemination + educational program (increase ability)  G3: Guideline dissemination + educational program + individualized treatment advice based on airway responsiveness and symptoms (multicomponent) | Clinical outcomes (applicable for general public/patients)  Usage of asthma medication. Number of PPD. For ICS this is mean PPD prescribed in 1 year. For β2 agonist it is mean number of PPD used during the diary period. | | NR  Objective measurement | | Overall N=362 G1: 98 G2: 133 G3: 131  Also conducted post-hoc analysis where Groups 1 and 2 were combined | | ICS G1: M =0.4 (SE=0.05)  G2: M=0.5(SE=0.05)  G3: M=0.6 (SE=0.05)   β2 agonist G1: M =0.45 (SE=0.01)  G2: M=0.43(SE=0.08)  G3: M=0.29 (SE=0.08) | | ICS G1 vs. G2: 0.1\* G1 vs.. G3: 0.2\* G2 vs. G3: 0.1\* Significant overall treatment effect among all 3 groups.  p=0.03  Significant difference between baseline and end of study for G3 (.1, P<0.05)  Post-hoc analysis (aggregated groups 1 & 2):  G1&G2 vs. G3: .2 Significant difference between groups p=0.02  β2 agonist G1 vs. G2: .02\* G1 vs. G3: .16\* G2 vs. G3: .14\* No significant treatment effect between 3 groups.  p=0.2  Significant different between baseline and send of study for G3 (-.24, p<0.05) | | NR  Mixed model ANOVA analyses | |

Table F-7. Key question 2 studies with a third outcome (continued)

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author, Year** | **Groups** | | **Outcome #3, Exact Measure Used** | | **Timing of Measurement,**  **Data Source** | | **N analyzed for This Outcome** | | **Results by Group** | | **Differences in Groups** | | **Covariates Controlled for in Analysis, Statistical Methods Used** | |
| Hagmolen et al., 200815 (continued) |  |  | |  | |  | |  | | Postanalysis:  G1&G2 vs. G3: .15\* No significant difference between groups. p=0.2 | |  | |
| Jain et al., 200616 | G1: Passive intervention- guidelines by mail (increase reach)  G2: Active intervention (multicomponent) | Clinical outcomes (applicable for general public/patients)  3 measures assess Clinical Outcomes.  Duration of ICU (reported in days, using the median, and the IQR is reported) Hospital length of stay (reported in median days, IQR. Followup was censored at 60 days so true upper quartile is undefined) 28-day mortality rate (reported as n, %) | | Baseline and 12 month followup  Observation | | Practice Overall=58 ICUs randomized as 50 clusters G1: 25 clusters G2: 25 clusters  Patients Baseline Overall=623 G1: 298 G2: 325 Followup Overall=612 G1: 305 G2: 307  Note: the patients were not the same at baseline and followup. The authors took a cross-sectional survey at both time points. | | ICU LOS (median, IQR) Baseline G1: 14.9 (8.3/29.9) G2: 14.4 (7.3/32.3) Followup G1: 13.7 (7.8/28.5) G2: 13.9 (8.6/33.4)  Hospital LOS (median, IQR) Baseline G1: 27.4 (15.3/60) G2: 28.2 (14.4/60) Followup G1: 28.8 (15.0/60) G2: 29.1 (14.7/60)  28 day mortality (n, %) Baseline G1: 63 (21.1%) G2: 68 (20.9%) Followup G1: 56 (18.4%) G2: 56 (18.2%) | | No significant differences in change  ICU LOS ΔG1 : -1.2\* ΔG2: -0.5\* ΔG1-ΔG2: 0.7\* p=NR  Hospital LOS ΔG1 : 1.4\* ΔG2: 0.9\* ΔG1-ΔG2: 0.5\* p=NR  28 day mortality ΔG1 : -2.7%\* ΔG2: -2.7\* ΔG1-ΔG2: 0\* p=NR | | NR  Fisher’s randomization test of the log-rank statistic | |

Table F-7. Key question 2 studies with a third outcome (continued)

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author, Year** | **Groups** | | **Outcome #3, Exact Measure Used** | | **Timing of Measurement,**  **Data Source** | | **N analyzed for This Outcome** | | **Results by Group** | | **Differences in Groups** | | **Covariates Controlled for in Analysis, Statistical Methods Used** | |
| Kennedy et al., 200319 | G1: Control (not abstracted)  G2: Information (increase reach)  G3: Interview (increase motivation) | Behavioral intentions to use or apply the evidence  Preference at baseline a binary variable was used: 0 = no preference held postconsultation and 1 = preference formed post consultation. For those who did hold a preference at baseline a nominal variable was produced with three categories: preference maintained, preference changed, no preference (the woman no longer held a preference postconsultation). | | Baseline and postconsultation.  Self-report | | Overall=685 G2: 234 G3: 226 | | Women with no preference at baseline #, % G2: 135, 57.7% G3: 114, 50.4% | | Only reported differences between each group and the control | | Consultant sex; Consultant year of qualification; Age; Baseline menorrhagia severity; Baseline knowledge; Previous treatment – D&C; Previous treatment – OCP; Previous treatment – hormonal drugs; Previous treatment – non-hormonal drugs; Duration of problem; Any previous surgery; Baseline preferences (where preference held at baseline); Recruitment period  Multinomial logistic regression | |

Table F-7. Key question 2 studies with a third outcome (continued)

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author, Year** | **Groups** | | **Outcome #3, Exact Measure Used** | | **Timing of Measurement,**  **Data Source** | | **N analyzed for This Outcome** | | **Results by Group** | | **Differences in Groups** | | **Covariates Controlled for in Analysis, Statistical Methods Used** | |
| Lien et al., 2007,22 Svetkey et al., 2003,23 Young et al., 200924 | G1: Advice only (increase reach)  G2: Advice + behavioral counseling using established intervention (multicomponent)  G3: Established intervention + DASH dietary recommendations (multicomponent) | Clinical outcomes (applicable for general public/patients)  Percent that met at least 3 health goals | | 6-months and 18 months  Objective measurement | | N at 6 months G1: 248 G2: 239 G3: 242 N at 18 months G1: 254 G2: 244 G3: 254 | | 6 months: G1: 11.7%  G2: 19.3% G3: 44.6%  18 months G1: 11.0% G2: 11.9% G3: 33.5% | | 6 months: G2-G1: 7.6%\* p<0 .02 G3-G1: 32.9%\* p<0 .0001 G3-G2: 25.3%\* p<0 .0001 18 months: G2-G1: 0.9%\* p=NR, but non-significant G3-G1: 22.5%\* P<0 .0001 G3-G2: 21.6%\* p< 0.0001 | | None  Mantzel-Haenzel chi-squared | |

Table F-7. Key question 2 studies with a third outcome (continued)

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author, Year** | **Groups** | | **Outcome #3, Exact Measure Used** | | **Timing of Measurement,**  **Data Source** | | **N analyzed for This Outcome** | | **Results by Group** | | **Differences in Groups** | | **Covariates Controlled for in Analysis, Statistical Methods Used** |
| Marcus et al., 200925 | G1: Contact control treatment delayed group (not abstracted)  G2: Telephone-based individualized feedback (increase motivation)  G3: Print-based individualized feedback (increase reach) | Behavioral intentions to use or apply the evidence  Decisionmaking for exercise measured by decisional balance instrument by Marcus, et al. | | Baseline, 6 and 12 months  Self-report | | NR | | G1: 6 Months: -2.95; 12 Months: -3.64 G2: 6 Months: 13.38; 12 Months: -0.75  G3: 6 Months: 15.45; 12 Months: 14.12 | | Difference: 6 Months: F=4.49; 12 Months: F=6.04 95% CI: NR 6 Months:  p<0.0122  12 Months: p<0.0028 | | Yes  Analysis of covariance, adjusted for treatment effects for gender and seasonal differences. When overall test of between-groups differences was significant at the >05 level, the source of these differences was examined further using single-degree-of-freedom contrasts that compared the active treatment arms with each other as well as with the treatment delayed group. | |

Table F-7. Key question 2 studies with a third outcome (continued)

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author, Year** | **Groups** | | **Outcome #3, Exact Measure Used** | | **Timing of Measurement,**  **Data Source** | | **N analyzed for This Outcome** | | **Results by Group** | | **Differences in Groups** | | **Covariates Controlled for in Analysis, Statistical Methods Used** |
| Murtaugh et al.,200527 | G1: Usual care (not abstracted)  G2: Basic intervention email reminder (increase reach)  G3: Augmented intervention of email reminder + package of supporting materials (multicomponent) | Discussions about the evidence  % giving patients instructions about Shortness of breath | | chart-review of subsequent RN visit, within 45 days of initial intake  Chart | | 354 | | Overall N=354 G1: 18.1% G2: 31.1% G3: 28.9% | | Difference G2-G1: 13.0%, p=0.021  Difference G3-G1: 10.8%, p=0.053 Difference G3-G2: -2.2%\*, CI and p=NR | | Socio-demographic variables of the RN (age, gender, race/ethnicity), Rn employment status, educational level and caseload; average baseline characteristics of patients care for by each RN including health, functional status; geographic area where nurse provided care  Predictive multivariate modeling | |

Table F-7. Key question 2 studies with a third outcome (continued)

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author, Year** | **Groups** | | **Outcome #3, Exact Measure Used** | | **Timing of Measurement,**  **Data Source** | | **N analyzed for This Outcome** | | **Results by Group** | | **Differences in Groups** | | **Covariates Controlled for in Analysis, Statistical Methods Used** | |
| Paradis et al.,201128 | G1: Paper handouts (increase reach)  G2: Educational DVD (increase reach) | Clinical outcomes (applicable for general public/patients)  Health care utilization including the # of additional clinic visits, # of parent-initiated phone calls, total # of professional consultations, proportion with >1 additional visit, and # of emergency dept visits between the enrollment visit and the 2 month well-child visit.   “Professional consultations” -- the combination of clinic visits and parent-initiated phone calls.   Additional office visits -- any (problem-related) visit outside of the usual well-child schedule | | 2 months postenrollment  Chart | | Overall N=137 G1: 67 G2: 70 | | Number of additional clinic visits: G1: 2.0 (SD=1.1) G2: 1.6 (SD=1.2) Number of parent-initiated phone calls: G1: 1.8 (SD=1.9) G2: 1.1 (SD=1.8) Total professional consultations: G1: 4.0 (SD=3.0) G2: 2.9 (SD=2.8) Proportion with >1 additional visit: G1: 42 (63%) G2: 27 (39%) Number of emergency department visits: G1: 0.2 (SD = 0.6) G2: 0.2 (SD = 0.5) | | Number of additional clinic visits: G2-G1: - 0.4,  95% CI: -0.80 to -0.01 p=0.05  Number of parent-initiated phone calls: G2-G1:  -0.7, 95% CI: -1.22 to -0.01 p=0.05  Total professional consultations: G2-G1:  -1.1, 95% CI: -2.00 to -0.03 p=0.04  Proportion with >1 additional visit: G2-G1:  -15, 95% CI NR p=0.01  Number of emergency department visits: G2-G1:  0, 95% CI: -0.20 to 0.18 p=0.91 | | Hispanic ethnicity, babies born at outside hospital, #exclusively breast fed  Multivariate regression analysis | |

Table F-7. Key question 2 studies with a third outcome (continued)

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author, Year** | **Groups** | | **Outcome #3, Exact Measure Used** | | **Timing of Measurement,**  **Data Source** | | **N analyzed for This Outcome** | | **Results by Group** | | **Differences in Groups** | | **Covariates Controlled for in Analysis, Statistical Methods Used** | |
| Partin et al., 200429 | G1: Usual care (not abstracted)  G2: Pamphlet (increase reach)  G3: Video (increase reach) | Discussions about the evidence  Patient participation in CaP screening decisionmaking was assessed by a single question about whether CaP screening was discussed at their last clinic visit. | | 1 week posttarget appointment  self-report | | N=893 G2: 295 G3: 308 | | Unadjusted proportions  G2: 0.41 G3: 0.35 Adjusted proportions G2: .35 G3: .41 | | Unadjusted  G2 vs. G3: 0.06\*,  p=NR Adjusted G2 vs. G3: 0.06\*,  p=NR | | Adjusted analysis accounted for marital status, education, race, health status, comorbid conditions, experience with prostate problems, symptom severity, medication use  logistic regression | |

Table F-7. Key question 2 studies with a third outcome (continued)

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author, Year** | **Groups** | | **Outcome #3, Exact Measure Used** | | **Timing of Measurement,**  **Data Source** | | **N analyzed for This Outcome** | | **Results by Group** | | **Differences in Groups** | | **Covariates Controlled for in Analysis, Statistical Methods Used** | |
| Rebbeck et al., 200631 | G1: Dissemination of guidelines by mail (increase reach)  G2: Implementation group (multicomponent) | Clinical outcomes (applicable for general public/patients)  Disability due to acute whiplash - measured more specifically using a 5-item adapted version of the Core Outcome Measure for neck pain. Each item was scored on a 5-point response scale. Summation of the 5 items yields a score ranging from 5 to 25; higher scores indicate greater perceived disability. | | Baseline, month 1.5, month 3, month 6, month 12  Self-report | | Baseline: G1: 28 G2: 71 Month 1.5 G1: 24 G2: 64 Month 3 G1: 23 G2: 59 Month 6 G1: 19 G2: 56 Month 12 G1: 26 G2: 67 | | Baseline: G1: M=15.5, SD=3.2 G2: 16.3, SD=3.7 Month 1.5 G1: 10.9, SD=3.8 G2: 13.5, SD=4.9 Month 3 G1: 10.2, SD=3.7 G2: 11.5, SD=4.4 Month 6 G1: 9.4, SD=4.3 G2: 10.9, SD=5.2 Month 12 G1: 10.0, SD=4.2 G2: 10.3, SD=4.4 | | Baseline Difference (G1 vs. G2): 0.3\* 95% CI: -2.1 to 2.7 p=0.08 Month 1.5 Difference (G1 vs. G2): 2.8\* 95% CI: -0.5 to 6.2 p=0.09 Month 3 Difference (G1 vs. G2): 1.3\* 95% CI: -1.3 to 3.8 p=0.31 Month 6 Difference (G1 vs. G2): 1.7\* 95% CI: -2.3 to 5.7 p=0.38 Month 12 Difference (G1 vs. G2): 0.3\*  95% CI: -2.4 to 3.0 p=0.85 | | NR  t-test, adjusted using methods for cluster-randomized trials | |

Table F-7. Key question 2 studies with a third outcome (continued)

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author, Year** | **Groups** | | **Outcome #3, Exact Measure Used** | | **Timing of Measurement,**  **Data Source** | | **N analyzed for This Outcome** | | **Results by Group** | | **Differences in Groups** | | **Covariates Controlled for in Analysis, Statistical Methods Used** | |
| Rimer et al., 200132 | G1: No treatment control/usual care (not abstracted)  G2: Tailored print (increase reach)  G3: Tailored print + telephone counseling (multicomponent) | Knowledge about the evidence  2 true/false questions on breast CA and mammography (% correct):  1) Mammograms are more effective for women 50-65.  2) Women over 50 are at higher risk for breast cancer | | 1 week following receipt of intervention  Self-report | | 1127 | | Mammograms are more effective for women 50-65, % correct: G1: 11% G2: 15% G3: 20%  Women over 50 are at higher risk for breast cancer, % correct G1: 25% G2: 27% G3: 37% | | Absolute difference in knowledge, mammogram effectiveness:  G2-G1: +4%\*, p=NS G3-G1: +9%\*, p<0.05 G3-G2: +5%\*, p=NS Any difference in groups: p=0.007  Absolute difference in knowledge, risk for cancer:  G2-G1: +2%\*, p NS G3-G1: +12%\*, p<0.05 G3-G2: +10%\*, p<0.05 Any difference in groups: p=0.001 | | None  Pearson chi-square and F-test | |
| Simon et al., 200534 | G1: Mailed educational materials (increase reach)  G2: Individual academic detailing (increase ability)  G3: Group academic detailing (increase ability) | Clinical outcomes (applicable for general public/patients)  Rates of hospitalization (from electronic medical record) | | Baseline and 1 year followup  Objective | | Baseline: 3692 Year 1: 2142 | | Baseline G1: 0.26, SD=0.94 G2: 0.26, SD=0.79 G3: 0.25, SD=0.77  Year 1 G1: 0.21, SD=0.79 G2: 0.18, SD=0.63 G3: 0.22, SD=0.69 | | Year 1 G1 vs. G2: 0.03\* G1 vs. G3: 0.01\* G2 vs. G3: 0.04\* | | Differences among individual patients  Descriptive statistics (for determining M) | |

Table F-7. Key question 2 studies with a third outcome (continued)

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author, Year** | **Groups** | | **Outcome #3, Exact Measure Used** | | **Timing of Measurement,**  **Data Source** | | **N analyzed for This Outcome** | | **Results by Group** | | **Differences in Groups** | | **Covariates Controlled for in Analysis, Statistical Methods Used** | |
| Soler et al., 201035 | G1: Control (not abstracted)  G2: Training session on the SEPAR guidelines (increase ability)  G3: G2 + portable-device for spirometry (multicomponent) | Clinical outcomes (applicable for general public/patients)  Differences in Treatment Regime (distribution of drugs prescribed according to the severity (mild vs. severe) of COPD before and after the training session. Treatment regimens: fixed combination, bronchodilators, corticoids and antibiotics. | | Starting 90 days after training session  Chart | | G1: 1481,  G2: 2119,  G3: 5556 | | Long acting beta agonist: G1: 36.5% G2: 17.2% G3: 17%  Anticholinergics: G1: 68.1% G2: 76.1% G3: 77.8%  Theophylline G1: 5.5% G2:7.6% G3:4.9% | | Long acting beta agonist: G2- G1: 19.3%, p=NR G3-G1: 19.5%, p=NR  Anticholinergics: G2-G1: +8%, p= NR G3-G1: +9.7%  Theophylline G2-G1: +2.1%, p=NR G3-G1: -0.6, p=NR | | baseline value  Logistic regression | |
| Wolters et al., 200539 | G1: Control mailed guidelines (increase reach)  G2: Intervention involving package for learning, supporting materials, decision tree, and information leaflets for patients (multicomponent) | Behavior (applicable for clinicians)  Adherence to guidelines. Number of patients referred to a urologist. The lower the referral rate, the better.  More following of a watchful waiting policy | | Up to 1 year postintervention  Prospective recording of patient data and management immediately after consultation with eligible patient | | N=187  G1: 92 G2: 95 | | Referral G1: 13, 14.5% G2: 2,2.1%  Wait and see approach G1: 54, 58.7 G2: 61, 64.2% | | Referral  G1 vs. G2: 12.4%\* OR:0.08 (0.02/0.40) Wait and see G1 vs. G2: 5.5%\* OR:1.47 (0.66/3.28) | | Age, group allocation, IPSS and BS  Logistic regression | |

\* calculated by reviewer   
**Abbreviations:** ANOVA = ANalysis Of Variance; BS=Bother score; CaP = Cancer of the Prostate; CI = confidence interval; COPD = chronic obstructive pulmonary disease; CRC = colorectal cancer; DASH = Dietary Approaches to Stop Hypertension; dept = department; DVD = optical disc storage format; EMR = electronic medical record; FOBT = fecal occult blood test; G = group; ICS=inhaled corticosteroid; ICU = intensive care unit; IPSS=International Prostate Symptom Score; IQR = interquartile ratio; LHA = lay health advisor; LOS=length of stay; M=Mean; N=number; NR = not reported; NRS=Numeric rating scale; NS=not significant; OCP=oral contraceptive pill; PPD = puffs per day; QOL = quality of life; RN=registered nurse; SD = standard deviation; SEPAR = Spanish Society of Pulmonology; TPV = tailored and targeted print and video; UC = usual care; WCB = Workers Compensation Board;